HAEM5:Volunteer Assignments and Opportunities: Difference between revisions
| [unchecked revision] | [unchecked revision] |
No edit summary |
No edit summary |
||
| Line 44: | Line 44: | ||
|Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive | |Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive | ||
|Jack Reid, MD (University of California, Irvine) Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | |Jack Reid, MD (University of California, Irvine) Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | ||
| | |Complete | ||
|Date page was created | |Date page was created | ||
| | | | ||
| Line 51: | Line 51: | ||
|Chronic Neutrophilic Leukemia (CNL) | |Chronic Neutrophilic Leukemia (CNL) | ||
|Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine <nowiki>**</nowiki>contributed equally | |Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine <nowiki>**</nowiki>contributed equally | ||
| | |Complete | ||
|Date page was created | |Date page was created | ||
| | | | ||
| Line 58: | Line 58: | ||
|Chronic Eosinophilic Leukemia, Not Otherwise Specified | |Chronic Eosinophilic Leukemia, Not Otherwise Specified | ||
|Chelsea D. Kramish; Daynna J.Wolff | |Chelsea D. Kramish; Daynna J.Wolff | ||
| | |complete/pending faculty review | ||
| | | | ||
| | | | ||
| Line 65: | Line 65: | ||
|Polycythemia Vera (PV) | |Polycythemia Vera (PV) | ||
|Gokce A. Toruner, MD, PhD UT MD Anderson Cancer Center | |Gokce A. Toruner, MD, PhD UT MD Anderson Cancer Center | ||
| | |Complete | ||
| | | | ||
| | | | ||
| Line 72: | Line 72: | ||
|Essential Thrombocythemia (ET) | |Essential Thrombocythemia (ET) | ||
|Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN | |Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN | ||
| | |Complete | ||
| | | | ||
| | | | ||
|- | |- | ||
|Primary myelofibrosis||Disease|| | |Primary myelofibrosis||Disease|| || || || || ||FQR|| || | ||
| | |Primary Myelofibrosis (PMF) | ||
| | |T. Niroshi Senaratne, UCLA | ||
| | |Complete | ||
|8/4/2020 before submission<br /> | |8/4/2020 before submission<br /> | ||
| | | | ||